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SUMMARY More than 85% of the global population
requires repair or replacement of a craniofacial
structure. These defects range from simple tooth
decay to radical oncologic craniofacial resection.
Regeneration of oral and craniofacial tissues presents
a formidable challenge that requires synthesis of
basic science, clinical science and engineering tech-
nology. Identification of appropriate scaffolds, cell
sources and spatial and temporal signals (the tissue
engineering triad) is necessary to optimize develop-
ment of a single tissue, hybrid organ or interface.
Furthermore, combining the understanding of the
interactions between molecules of the extracellular
matrix and attached cells with an understanding of
the gene expression needed to induce differentiation
and tissue growth will provide the design basis for
translating basic science into rationally developed
components of this tissue engineering triad. Dental
tissue engineers are interested in regeneration of
teeth, oral mucosa, salivary glands, bone and perio-
dontium. Many of these oral structures are hybrid
tissues. For example, engineering the periodontium
requires growth of alveolar bone, cementum and the
periodontal ligament. Recapitulation of biological
development of hybrid tissues and interfaces pre-
sents a challenge that exceeds that of engineering just
a single tissue. Advances made in dental interface
engineering will allow these tissues to serve as model
systems for engineering other tissues or organs of the
body. This review will begin by covering basic tissue
engineering principles and strategic design of func-
tional biomaterials. We will then explore the impact
of biomaterials design on the status of craniofacial
tissue engineering and current challenges and oppor-
tunities in dental tissue engineering.
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I. Introduction: clinical need for tissue
engineering
Defects in oral and craniofacial tissues, resulting from
trauma, congenital abnormalities, oncological resection
or progressive deforming diseases, present a formidable
challenge and restoration of these tissues is a subject of
clinical, basic science and engineering concern (1, 2). In
addition to leaving patients with aesthetic deformities,
oral and craniofacial defects may be uncomfortable to
the patient and affect function. Thus, structure, func-
tion, aesthetics and pain must all be managed effec-
tively resulting in treatment challenges that are often
more complex than in other parts of the body. In
addition to problems associated with cranial and facial
tissues, 15% of the US population has periodontal
disease severe enough to warrant surgery (1). It is
further estimated that 9–15 million people in the US
experience temporomandibular joint (TMJ) disorders
(3), over 30 000 per year have undergone craniofacial
resective surgery (4), 2–4 million suffer from salivary
gland hypofunction (5) and 85% require replacement
or repair of one or more teeth (6). Expansion of these
figures to include worldwide dental and craniofacial
needs provides staggering support for the need to
engineer dental and craniofacial tissues.
In many cases, tissues of the craniofacial complex
need to be repaired because of structural deficiencies.
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There is, however, inadequate guidance regarding
patient-selection criteria for many procedures, such as
TMJ reconstruction (4, 7). Surgical treatment of TMJ,
periodontal and other craniofacial defects is therefore
not predictable and does not fully restore function to the
tissues in many cases (1). Collectively, therefore, defects
associated with orofacial tissues may result in aesthetic
deformity, pain and reduced function and represent a
substantial clinical problem in need of new solutions.
Techniques to repair orofacial defects parallel
accepted therapies for restoring tissue structure and ⁄ or
function elsewhere in the body, and include synthetic
materials, autografts and allografts (8–10). Each of
these reconstructive strategies has limitations and lacks
clinical predictability. Only a minimal amount of tissue
can be harvested for autografts, the harvesting proce-
dure may lead to donor site discomfort and morbidity
and it may be difficult to form this tissue into desired
shapes (8–10), a problem that is particularly important
in the craniofacial region. Autografting, the current
‘gold standard’ for bone regeneration, has failure rates
as high as 30% (11). Allografts have the potential of
transferring pathogens (12). Freeze-drying, demineral-
ization and irradiation to reduce immunogenic poten-
tial can also reduce structural integrity, leading to graft
fracture (12). Other complications with autografts and
allografts include unreliable incorporation, resorption
and non-union of the graft ⁄ host tissue interface (13,
14). Induction of new tissue by growth factors requires
large amounts of recombinant material, which may not
be realistic in cases of massive defects (15). Addition-
ally, successful use of growth factors relies on the
presence of a sufficient population of undifferentiated
progenitor cells capable of responding to the inductive
cues provided by the growth factor (16). Such a
population may not be available in aged or compro-
mised patients.
Synthetic materials are primarily designed to be
permanently implanted. Long-term complications in-
clude stress shielding, loosening and mechanical or
chemical breakdown of the material itself (8, 9, 17).
Demographics on total joint replacements, such as TMJ
replacements, indicate that 25% of the procedures
performed each year are revisions (18). Many TMJ
patients have had multiple surgeries and the greater the
number of surgical procedures, the lower the chance for
functional improvement. Of particular importance with
the use of synthetic materials is that most problems
manifest themselves at the biomaterial ⁄ tissue interface,
in part because the tissue has the ability to adapt
functionally, whereas the synthetic material does not.
More biologically interactive biomaterials could poten-
tially solve the problem of implant ⁄ tissue interface
failure and improve the clinical treatment of craniofacial
defects. The desire to create more biological alternatives
to the permanent implantation of static synthetic
materials has inspired the field of tissue engineering.
The basic premise of tissue engineering is that controlled
manipulation (engineering) of the extracellular micro-
environment can lead to control over the ability of cells
to organize, grow, differentiate, form a functional
extracellular matrix (ECM) and, ultimately, new func-
tional tissue. Such control is a complex process that
requires autocrine, paracrine and endocrine signals,
positional cues, cell-matrix interactions, mechanical
forces and cell-cell contacts to mediate the formation
of 3D tissue architecture and function. In the last
decade, many advances in oral and craniofacial tissue
engineering have been made, including the in vitro and
in vivo engineering of craniofacial bone (19, 20), cranial
sutures (21), periodontium (16, 22–24), oral mucosa
(25, 26), tooth-associated structures (27–29) and the
TMJ (30–33) from combinations of biomaterials, stem
cells and ⁄ or recombinant growth factors.
This review will examine advances in tissue engi-
neering of craniofacial structures. Following a summary
of the principles of tissue engineering, advances in
biomaterials used to engineer tissue structure and
function will be reviewed. Focus is placed on second
generation biomaterials for tissue engineering, which
are more biologically interactive and mimic some of the
regulatory aspects of the ECM. Building upon the
principles of tissue engineering and material design
strategies presented, specific dental and craniofacial
applications, including engineering of teeth, periodon-
tium, the TMJ, skin, oral mucosa and salivary glands
will be discussed with emphasis on application of cells,
scaffolds and signalling strategies. Lastly, issues unique
to engineering oral and craniofacial tissues will be
discussed, along with the difficulties in engineering
craniofacial tissues versus tissues elsewhere in the body.
The potential for oral tissues to serve as model tissue
engineering systems is also discussed.
II. Tissue engineering principles
To engineer functional tissues, cells (host and ⁄ or
donor) must be provided with appropriate spatial and
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temporal cues to enable growth, differentiation and
synthesis of an ECM of sufficient volume and func-
tional integrity. Explicit in the definition of tissue
engineering (34) is the need to understand structure-
function relations in normal and diseased tissues and to
use these insights as design criteria for engineering new
tissues. Upon understanding how tissues develop in vivo
and what constituents are most critical for eliciting
function, such information can be used in design
strategies to recapitulate aspects of developmental
biology. Structure-function relations and resultant
design strategies are needed at multiple levels of
dimensional scale and challenges include deciphering
what ‘instructions’ cells need to organize into tissues,
which cells should be targeted and what level of
hierarchy is most critical to control. Tissue engineering
goes beyond regenerative medicine and incorporates
the unique qualities of engineering design and use of
the engineering method (35) as bases for developing
the approaches used to control biological systems.
Many tissue engineering approaches are based on the
tissue engineering triad, which was derived from the
three major components of tissues: cells, their ECM and
a signalling system (36) (Fig. 1). A functional tissue can
be developed via the use of one or more of these
components. Combining the understanding of the
interactions between molecules of the ECM and
attached cells with an understanding of the gene
expression needed to induce differentiation and tissue
specific growth provides the design basis for translating
basic science into rationally developed components of
the tissue engineering triad.
Biomaterials are clearly central to the advancement
of tissue engineering and a variety of biomaterial
‘scaffolds’ have been developed as ECM analogues
capable of supporting cell attachment (e.g. conduction)
and, in some cases, providing the cues necessary for
controlled spatial and temporal development (e.g.
induction). In addition to material-based means of
controlling cell fate, soluble or insoluble instructional
molecules may be used to provide guidance to cells.
Materials and signals can be used to provide instruction
to host and ⁄ or donor cells, with control of cell growth
and differentiation manipulated via exogeneous (e.g.
engineering the extracellular microenvironment) or
endogeneous (e.g. genetic engineering) means.
Each component of the tissue engineering triad may
be implemented in a variety of ways. Some of the
challenges in tissue engineering involve identifying the
most appropriate form of each constituent of the tissue
engineering triad for a specific application. For exam-
ple, the material, as well as its form (gel, foam or fibre)
can significantly affect biological response (37, 38).
Likewise, identification of appropriate cell sources for a
desired application [autogenous versus allogenic cells;
primary cells, cell lines, genetically modified cells versus
stem cells; adult versus embryonic cells; mesenchymal
versus pulpal versus adipose versus periodontal liga-
ment stem cells (PLSCs)] is a core challenge in tissue
engineering (39–41) that will be discussed later in this
review in the context of specific dental tissues. Identi-
fication of spatial and temporal signals (e.g. growth
factors, cytokines, chemokines) for tissue-specific dif-
ferentiation and morphogenesis and the approach to
deliver these signals (soluble versus insoluble; temporal
and spatial control) represent design choices along the
third axis of the tissue engineering triad (16, 42).
One common strategy is to create a composite graft in
which cells from any of the sources mentioned above
are seeded into a degradable biomaterial (scaffold) that
can serve as an ECM analogue and support cell
adhesion, proliferation, differentiation and secretion









Fig. 1. The Tissue Engineering Triad (228). The three main design
components in tissue engineering are based on the three main
components of tissues: cells, their extracellular matrix (scaffolds)
and a signalling system. Each of these components represents a
design strategy, cell transplantation, conduction and induction,
respectively, which can be used individually or in combination to
optimize regeneration and engineering of a functional tissue
[Figure reprinted with permission from (228)]. In this review,
several specific design considerations for each component have
been highlighted. Throughout the text, these considerations and
their implications for oral tissue engineering will be explored.
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constructs may be immediately implanted or cultured
further and then implanted. In the latter case, the cells
proliferate and secrete new ECM and factors necessary
for tissue growth in vitro and the biomaterial ⁄ tissue
construct is then implanted as a graft. Once implanted,
the scaffold is also populated by cells from surrounding
host tissue. Ideally, secretion of an ECM and subse-
quent tissue growth occur concurrently with scaffold
degradation. In the long-term, a functional ECM and
tissue are regenerated and are devoid of any residual
scaffold.
Utilizing the principles of tissue engineering in a
rational manner offers promise to regenerate or develop
de-novo oral and craniofacial tissues. As discussed later
in this review, dentistry can both capitalize on advances
made in the engineering of non-dental tissues and
organs, as well serve as a paradigm for the engineering
of non-dental tissues.
III. Design of materials for engineering
tissue structure and function
Historically, the biomaterials used in dentistry and
medicine had their origins in other fields. For example,
the acrylics used in dentures were developed in the
paint industry and base metals have their origin in the
aerospace industry. Although many biomaterials have
had a lengthy history of clinical success, very few
interact with their surrounding host environment or
promote integration with host tissue in an intelligent,
proactive fashion. The desire for more biological
approaches to biomaterials design that could yield
materials that are more instructive to cells has led to
an expansion and paradigm shift in the field of
biomaterials. The discipline of biomaterials now
extends beyond the field of materials science and
incorporates cell and molecular biology, genetics,
biochemistry and other engineering disciplines.
An ideal tissue substitute should possess the biolog-
ical advantages of an autograft and supply advantages
of an allograft, while alleviating the complications of
these grafts (43, 44). Such a construct should also
satisfy the following design requirements (8): (i)
biocompatibility, (ii) conductivity for attachment and
proliferation of committed cells or their progenitors and
production of new ECM, (iii) ability to incorporate
inductive factors to direct and enhance new tissue
growth, (iv) support of vascular ingrowth for oxygen
and biomolecule transport, (v) mechanical integrity to
support loads at the implant site, (vi) controlled,
predictable, reproducible rate of degradation into non-
toxic species that are easily metabolized or excreted and
(vii) easy and cost-effective processing into irregular 3D
shapes of sufficient size to fill clinically relevant defects.
Particularly difficult is the integration of criteria (iv)
and (v) into a single material design, as transport is
typically maximized by maximizing porosity, while
mechanical properties are frequently maximized by
minimizing porosity. Integration of criteria (ii) and (iii)
also presents materials design challenges that require
more biomimetic complexity than many of the current
simplified ECM mimics can provide.
First generation synthetic and natural materials that
mimic structural and ⁄ or functional aspects of natural
ECMs and satisfy at least some of the design require-
ments listed above include both organic and inorganic
biomaterials: co-polymers of polylactic-glycolic acid
(45, 46), collagen (20), poly-phosphazenes (47), poly-
urethanes (48), polycaprolactone (49), polyethylene
glycol (PEG) (50), poly (propylene fumarate) (51),
starch-based materials (52), alginate (53), silk (54),
bioactive glasses and glass ceramics (55, 56), calcium-
phosphate ceramics (15, 57), calcium-phosphate and
collagen blends (20) and synthetic polymer ⁄ apatite
composites (58–60). Varying parameters of the bioma-
terial, such as composition, topology and crystallinity,
even subtly, can lead to a significant variation in cell
attachment and proliferation, protein synthesis and
RNA transcription in vitro (61–63). The parameters of
the scaffold can also significantly affect progenitor cell
differentiation, amount and rate of tissue formation,
and intensity or duration of any transient or sustained
inflammatory response in vivo (8, 37, 57, 64).
To extend performance beyond the capabilities of
these first generation tissue engineering scaffolds and
incorporate more of the above design criteria into a
single material, better control of biofunctionality is
needed. In particular, the specifics of the microenvi-
ronment that the material will interact with must be
taken into consideration in the design process, such
that remodeling and functionality can be maintained
in the long term. The complexity of this design process
is exemplified by the dynamic states of cells and
tissues, which are regulated by the spatial and
temporal coordination of multiple cell processes, each
of which in turn is regulated by multiple reciprocal
interactions between cells and their extracellular
microenvironment.
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Biomaterial modification can take on different levels
of complexity, resulting in increasing levels of physio-
logical ‘mimicry’ and functionality. In addition to using
natural ECMs, surface and bulk chemical modifications
of synthetic materials can enhance integration. Material
modifications include changes in hydrophilicity, surface
functionalization with charged groups, incorporation
of insoluble ligands and peptide cell recognition
sequences, attachment of larger proteins, supramole-
cular self-assembly and development of materials that
bind and release soluble factors (42, 65). Strategies
based on physical cues include the reproduction of
nanoscale topology, superposition of mechanical cues
and control of degradation. Designing biological recog-
nition into a biomaterial may also obviate the need for
therapies based on delivery of cells or recombinant
growth factors, which are subject to regulatory
constraints. More detail on these strategies is presented
in section IV, within the context of specific dental and
craniofacial tissue engineering applications.
IV. Dental and craniofacial tissue
engineering applications
A. Tooth and periodontium
Advances in engineering and dentistry have led to the
overwhelming success of dental implants. However,
many patients continue to inquire about the regrowth
or regeneration of their natural teeth. The goal of tooth
regeneration is complicated by the nature of the tooth
itself. An intact tooth is composed of four distinct
tissues; mesenchymal derived pulp, dentin, cementum
and epithelial derived enamel. The tooth root is then
supported by a proprioceptive periodontal ligament
(PDL) and encased in alveolar bone. This diversity in
tissue types coupled with the need for the tooth to
withstand forces of mastication makes tissue engineer-
ing of the dentition quite complex. Regeneration of the
tooth or its supporting structures has been the focus of
much effort in the last two decades (66). While some
groups focus on regenerating one or two of the sub-
tissues for targeted repair, others have moved towards
regrowing an intact tooth and alveolus simultaneously
for total replacement (67–69).
Unlike the many options available for bone tissue
engineering, whole tooth engineering maintains a
complete reliance on autologous stem cells due to our
lack of understanding of the complex signalling required
for shape specification, tissue interface and eruption.
Complete tooth regeneration is further complicated by
the fact that regrowth of a tooth is desired at a site where
a tooth no longer exists. Thus, unlike engineering bone
and mucosa, where scaffolds and signals can draw on
cues and cells present in the surrounding host tissue, an
ideal engineered tooth implant must be self-reliant.
Non-stem cell based strategies have been developed for
regeneration and repair of single dental tissues such as
pulp (70), dentin (70, 71), cementum (29) and enamel
(72) and may later inform efforts to generate multi-
tissue organs and functional interfaces between dental
tissues. This section will begin by outlining the stem cell
sources available for tooth repair and regeneration,
continue with a discussion of more advanced scaffold
technologies for craniofacial and periodontal bone tissue
engineering and end with a look at current clinical
prospects for these emerging technologies. Although the
details of many cellular, scaffold and signalling strategies
have been confined to this section, it is important to
recognize that similar methods are highly relevant to
engineering of TMJ, mucosa and salivary gland.
A.1. Cells Enamel is the most highly mineralized tissue
in the biological world and when fully mature contains
<4% organic material by weight (73). The basic
structural unit of enamel is the enamel rod. These rods
are secreted by epithelial derived ameloblasts. Amelo-
blasts undergo apoptosis as they elaborate the enamel
matrix leaving erupted teeth without an enamel pro-
genitor population.
Unlike enamel, the inner surface of dentin is lined by
matrix secreting odontoblasts that provide a low basal
level of tertiary or reactionary dentin formation
throughout life. These odontoblasts are derived from
dental pulp stem cells (DPSCs). Dental pulp stem cells
are a unique mesenchymal stem cell (MSC) population
that is present in the cell rich zone and core of the pulp
(74). Dental pulp stem cells have the ability to differ-
entiate into odontoblast-like cells, pulpal fibroblasts,
adipocytes and neural-like cells (74). Primary human
DPSCs maintain their stem-ness and continue to
express the stem cell surface marker Stro-1 even after
cryopreservation and extensive cell culture (75). The
transition of DPSC to odontoblast is accompanied by
deposition and mineralization of collagenous matrix
(76). In vivo transplantation of human DPSCs on a
hydroxyapatite (HA) ⁄ tri-calcium phosphate scaffold
subcutaneously in SCID mice results in generation of
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a dentin ⁄ pulp-like complex (77). This complex contains
vascularized pulp tissue with well-defined functional
odontoblasts lining mineralized primary dentin tissue.
While DPSCs have potential for dentin regeneration
and tooth repair, limited understanding of the molec-
ular regulation of DPSCs impacts our ability to use them
for clinical tissue engineering. As caries progresses
towards the pulp, the lining odontoblasts capable of
dentin regeneration may be lost. With the discovery of
this DPSC population, it may be possible to regenerate
new odontoblasts from an injured pulp that are capable
of repairing the carious dentin. Control of odontoblast
differentiation has been shown to be regulated by bone
morphogenic proteins (78), Wnt glycoproteins (79) and
Notch signalling (80). Further understanding of these
molecular regulators of differentiation and mineraliza-
tion will allow for co-ordinated dentin engineering and
aid tooth regeneration and repair efforts.
A second tooth-associated MSC population has been
isolated from the surrounding PDL, termed periodontal
ligament stem cells (PLSCs) (81). Since the 1980s,
evidence for the existence of this population and the
fact that it resides in a perivascular niche has been
steadily accumulating (82, 83). Periodontal ligament
stem cells and DPSCs maintain higher growth potential
than bone marrow stromal cells (BMSCs) when cul-
tured in vitro and proliferating colonies can undergo
over 100 population doublings before reaching quies-
cence (84). A correlation exists between this phenom-
enon and increased expression of cell cycle mediators
cyclin-dependent kinase-6 and insulin-like growth
factor (IGF)-2 (85–87). Periodontal ligament stem cells
are capable of regeneration of wounded periodontium
in rats and even surpass embryonic stem cells in their
repair capacity (88). These findings provide positive
support for those interested in cell-based therapies for
periodontitis, an inflammatory disease that results in
progressive loss of periodontal attachment and alveolar
bone.
Before eruption of a new tooth, a third population of
primitive stem cells in the tooth bud is capable of
providing the instructions necessary for growth of the
entire tooth. It is therefore reasonable to assume that
these cells could also regrow an entire tooth in vivo. One
of the first demonstrations of this phenomenon
occurred when a 2 mm square of foil was inserted into
the centre of a rat tooth bud in vivo. This resulted in two
teeth forming, one on each side of the foil, where
normally only one would be present (89). Anatomically
correct tooth crown formation was also achieved when
cells were isolated from rat or pig tooth bud, cultured
for up to 6 days and reimplanted into the omentum of
live rats (90, 91). After 12–30 weeks, implanted
cell ⁄ scaffold combinations demonstrated formation of
distinct pulp, predentin, dentin and enamel layers (73).
Advances in engineering whole teeth are limited by
the poor availability of human primitive tooth bud
stem cells and limitations in the ability to isolate and
purify them. Advances in purification include sorting
for STRO-1 positive (92) and Hoescht dye negative
cells (93) to enrich for primitive stem cells. Formation
of tooth crowns in vivo using primitive stem cells has
been accompanied by poor tooth root formation (67,
73). It appears that the transplanted cells lack the
ability or instructions necessary to form root dentin
and cementum that would be necessary to guide
eruption. It is possible that these signals are derived
from the supporting PDL or alveolar bone during
development. Indeed, when tissue engineered pig
tooth and alveolar bone are grown simultaneously in
rat omentum for 8 weeks, the development of a
primitive cementum layer and PDL is observed (67).
Further characterization of the molecular interactions
between these mixed mesenchymal and epithelial
populations and development of interface-supporting
biomaterials will allow increased control over tooth
regeneration in vivo.
A.2. Scaffolds Development of biomaterials capable of
supporting regrowth of the individual mineralized
tissues of the tooth and periodontium (bone, dentin,
cementum and enamel) and functionally graded
interfaces between these tissues is an active area of
research. Most current studies have used known
osteo-conductive materials to guide tooth and peri-
odontal engineering efforts and these materials parallel
those used in engineering other mineralized tissues.
Scaffolds including collagen (94–96), polyglycolic acid
(PGA) (94), self-assembling peptides (97), gelatin-
chondroitin-hyaluronan tri-copolymer (27) and silk
(54) have been used for tooth and periodontal
regeneration. The success of in vivo tooth regeneration
currently hovers around 20–50% with implanted
cell ⁄ scaffold combinations. The definition of success
varies, but generally includes the production of at
least three histologically intact structures including
enamel, dentin, pulp, cementum and PDL. Two novel
strategies that may improve the success of tooth
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regeneration and other areas of mineralized tissue
engineering include self-assembling peptides and
nanoscale biomaterials.
Self-assembling peptides or peptide amphiphiles are
based on principles of protein-protein interactions and
protein folding. All biomolecules self-assemble to form
well-defined structures that impart a specific function.
Nature has used proteins and peptides to synthesize an
array of materials whose hierarchy and function far
exceed those of man-made materials. By understanding
how supra-molecular structures are assembled in
nature, these processes can be exploited in the synthesis
of synthetic materials (98). Such approaches use non-
covalent intermolecular interactions to synthesize high-
er order structures via the self-assembly of biological
(nucleotide, oligomeric, peptide) and non-biological
amphiphilic building blocks. Self-assembling peptides
can support cell encapsulation, promote enamel rem-
ineralization by providing a bio-mimetic scaffold capa-
ble of HA nucleation, promote neural differentiation
and maintain the functions of differentiated chondro-
cytes (42, 97, 99, 100). Generation of an injectible self-
assembling peptide gel that could be applied to small
carious lesions to promote enamel remineralization is
one possible application of this scaffold technology (97).
Cell behaviour is also regulated by surface topology.
A variety of cell functions, such as adhesion and
intracellular signalling pathways, are sensitive to
micro- and nano-scale topology on the orders of
10–100 000 nm (101, 102). Creation of nano-fibrous
materials from ECM constituents or blends of synthetic
and natural polymers can provide a material with both
the physical scale necessary to influence biological
function and a biochemical composition that is similar
to the ECM environment that cells interact with in vivo
(42, 102, 103). The combination of physical and
biochemical cues can enhance cell adhesion, prolifer-
ation and tissue-specific differentiation, as well as
promote tissue integration in vivo. A key to translating
nano-technology into an implant that has clinical
relevance is to integrate the nanoscale features needed
to control cell function with a larger 3D implant that
has the dimensions and bulk properties required to
fulfill a desired dental application. One design approach
to achieve such an integration of dimensional scales in
a single material is to use bulk poly-crystalline materials
with grain sizes in the sub-micron range. Such mate-
rials exhibit enhanced biological responses, as well as
improved physical properties (104, 105). Reproduction
of nanoscale features exhibited by natural ECMs in a
tissue engineering scaffold has been achieved down to
the scale of 10 nm via the creation of nanofibrous
scaffolds. These scaffolds can be synthesized via well-
established materials synthesis approaches, including
electrospinning and thermally induced phase separa-
tion, as well as protein self-assembly (98, 106). Use of
nanoscale surface topology to enhance cell adhesion
and osseointegration has already established itself in
the context of dental implant processing and coating
(107) and will probably be expanded to larger scaffolds
designed to support osseous fill of periodontal and other
craniofacial defects (108).
In addition to soft materials, advances in nanoscale
inorganic biomimetic materials may impact future
engineering of the tooth and periodontium. Compared
with synthetic materials, natural biominerals reflect a
remarkable level of control in their composition, size,
shape and organization (109). A biomimetic mineral
surface could therefore promote preferential absorp-
tion of biological molecules that regulate cell function,
serving to promote events leading to cell-mediated
biomineralization (8). Bioactive ceramics bond to bone
through a layer of bone-like apatite, which forms on
the surfaces of these materials in vivo and is charac-
terized by a carbonate-containing apatite structure
with small crystallites (110, 111). A bone-like apatite
layer can be formed in vitro at standard temperature
and pressure (112–114), providing a way to control
the in vivo response to a biomaterial. Synthesis of
bone-like mineral in a biomimetic fashion is based on
the principles of biomineralization, in which organ-
isms use macromolecules to control mineral nucle-
ation and growth (109). Macromolecules usually
contain functional groups that are negatively charged
at the crystallization pH (109), enabling them to
chelate ions present in the surrounding media, which
stimulate mineral crystal nucleation (115). The self-
assembly of nanoscale mineral within the pores of a
polymer scaffold enhances cell adhesion, proliferation
and osteogenic differentiation and modulates cytoskel-
etal organization and cell motility in vitro (116, 117).
When osteoblast progenitor cells are transplanted on
these materials, a larger and more spatially uniform
volume of bone is regenerated, compared with non-
mineralized templates (117). The success of bone-like
apatites in bone tissue engineering is an encouraging
sign for the impact and use of biomimetic materials in
tooth and periodontal engineering.
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A.3. Signals In addition to its structural role the ECM
provides adhesive ligands such as fibronectin, vitronec-
tin and laminin that direct cell function. Reproduction
of these and other signals on engineered scaffolds can
allow a more precise regulation of cell function and
tissue formation. Incorporation of peptides to provide
specific instructive cues to cells, delivery of inductive
factors and control of cell-cell communication are three
approaches to optimize regeneration of craniofacial
structures. These approaches have clear applicability to
tooth and periodontal engineering and may expand
strategies to engineer whole teeth beyond just stem
cells.
Most biomaterials, especially polymers, will non-
specifically adsorb proteins through weak interactions
at the protein-water and biomaterial-water interfaces.
Incorporation of proteins or their sub-sequences into
the backbone of a polymer can control cell processes
such as differentiation and matrix degradation. Pro-
teins, growth factors and peptides have been ionically
or covalently attached to biomaterial surfaces to
increase cell adhesion and ultimately, the amount of
tissue regenerated. While several proteins enhance cell
adhesion, proteins are challenging to isolate and prone
to degradation (118, 119). Proteins can also change
conformation or orientation because they possess sec-
tions with varying hydrophobicities that address cellu-
lar functions other than adhesion. On the other hand,
peptides can mimic the same response as a protein
while being smaller, cheaper and less susceptible to
degradation. Peptides may therefore have a greater
potential for controlling initial biological activity be-
cause they can contain specific target amino acid
sequences and can permit control of hydrophilic prop-
erties through sequence design (119, 120).
The identification of peptide sequences within ECM
proteins that are responsible for cell adhesion led to the
development of peptide-functionalized biomaterials
(121). Incorporation of peptide motifs containing
sequences that are recognized by integrin receptors,
such as arginine-glycine-aspartic acid (RGD)-based
sequences PRGDSGYRGDS and DGRGDSVAYG, are
now a common strategy to enhance biological func-
tionality as well as proliferation and differentiation of a
variety of cells, including osteoblasts, odontoblasts,
fibroblasts and DPSCs (42, 119, 122–124). Materials
with RGD-containing sequences enhance cell adhesion
and direct differentiation into bone (125, 126), cartilage
(127, 128), neural (129) and endothelial tissue (4, 130)
and are therefore applicable to engineering tooth, bone,
cartilage and oral mucosa. Cell adhesion, migration and
lineage direction of cell phenotype are dependent on
ligand specificity, surface density, gradient, conforma-
tion and binding affinity (131). Using recombinant
DNA technology, synthetic proteins can be designed to
mimic specific ECM constituents. In addition to the
ubiquitous RGD sequence derived from the cell binding
domain of fibronectin and vitronectin, sequences
derived from the heparin binding domain, such as
FHRRIKA and KRSR, improve osteoblast adhesion and
mineralization (131–133) and RGD peptides derived
from dentin phosphophoryn and dentin matrix protein
1 promote selective attachment and migration of dental
pulp cells (124, 134). Peptide sequences that mimic
sections of collagen (135) and non-collagenous pro-
teins, including laminin (136), bone sialoprotein (137),
osteopontin (138), statherin (138), elastin (139) and
osteonectin (140) have also improved cell adhesion,
proliferation and differentiation of osteoblast-like cells
and may therefore promote function of other cells that
can form mineralized tissues of the oral cavity.
In addition to using recombinant technologies to
synthesize sequences within proteins known to pro-
mote a specific biological function, domains within a
protein can be deleted to investigate the effect of
targeted sequence deletions on the function of the
protein. Subsequently, sequences deemed to control a
specific function can be synthesized for use in a tissue
engineering application. Another discovery technique
is phage display, a high throughput approach in which
a bacterial phage library expressing combinations of
linear or cyclic peptide inserts is used to identify amino
acid sequences that have high affinity to a substrate or
cell type. Phage displays have identified sequences with
high affinity to cell lines cultured in vitro (141, 142),
cell ⁄ organ targets in vivo (143), enzymes and their
inhibitors and specific tissues (120, 144, 145). Phage
display technologies have also been used to isolate
peptide sequences attracted to inorganic or organic
materials (146–148). Most germane to craniofacial
tissue engineering is the use of phage display to identify
amino acid sequences with preferential affinity to the
bioactive materials HA and bone-like mineral (149).
The ECM has the ability to bind and release soluble
factors in a spatially and temporally controlled manner.
Inductive properties can be integrated into a material
using methods to immobilize proteins, such as adsorp-
tion, entrapment, cross-linking or covalent binding,
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each of which results in different loading efficiencies
and levels of protein retention (150). The method of
integrating organic factors into a biomaterial can
influence the resultant release profile and therefore
influence the response of surrounding cells. The con-
trolled release of a growth factor can be achieved by
incorporating the factor into the bulk of a scaffold or
hydrogel during polymerization and designing a release
profile based on drug diffusion and ⁄ or material degra-
dation. Many such systems have been developed for
drug delivery and several have been adapted to enable
macro-porous tissue engineering scaffolds to be used as
vehicles for delivery of bioactive factors (151–154).
Spheres or pellets with growth factor incorporated may
also be bound together to form a 3D construct.
Adsorbing or covalently binding a drug to each layer
of a material created by layer-by-layer assembly can
provide temporal control over its delivery (155). This
technology is most widely recognized in dentistry for its
use in delivery of microsphere encapsulated antibiotics
such as Minocycline hydrochloride to aid repair of
periodontal pockets (156).
Advances in the understanding of biomineralization
have resulted in the synthesis of mineral-organic
hybrids consisting of bone like apatites combined with
inductive factors to control cell proliferation, differen-
tiation and bone formation (154, 157). Organic ⁄ inor-
ganic hybrids show promise in combining the
osteoconductive properties provided by the apatite with
the osteoinductive potential provided by growth fac-
tors, DNA or peptides. Biomolecules can be incorpo-
rated at different stages of calcium phosphate
nucleation and growth (157) enabling spatial localiza-
tion of the biomolecule through the apatite thickness
and allowing for its controlled release. An advantage of
this approach is its ability to produce calcium phosphate
coatings at a physiological temperature, minimizing
conditions that would compromise the biological activ-
ity of the factors. Co-precipitation of mineral and
inductive molecules results in an increased protein
loading capacity and more controlled release in com-
parison with adsorption (157). Techniques used to
incorporate growth factors into bone-like mineral can
also be used to incorporate genetic material. The
mineral increases substrate stiffness (113), which also
enhances cellular uptake of plasmid DNA (158) pro-
viding an added advantage to such hybrid systems.
Most cell functions are dependent on multiple
signals, so delivery of multiple factors such as platelet
derived growth factor (PDGF), vascular endothelial
growth factor and bone morphogenetic proteins
(BMP) will probably result in greater advances in
periodontal tissue regeneration than delivery of a single
factor (159). As protein release from bone-like min-
eral ⁄ organic hybrid systems is proportional to apatite
dissolution, temporally controlling the release profile as
well as developing multi-factor delivery systems is
possible because of the ability to localize spatially the
protein within the biomimetically nucleated mineral
(157).
Gap junction intercellular communication (GJIC)
also plays a prominent role in the differentiation and
function of cells and their response to stimuli. As such,
it is possible to design materials or present signals to
cells that enhance GJIC (160). One example of the
potential for the controlled use of gap junctions in
tissue engineering involves a cell transplantation
approach, in which BMSCs are transduced with a
Cx43 lentivirus (160). Overexpression of Cx43 in
BMSCs leads to significant increases in GJIC and
elevated expression of alkaline phosphatase and osteo-
calcin in vitro, indicative of enhanced osteogenic
differentiation (160). Transplantation of cells trans-
duced with a Cx43 lentivirus also shows that over-
expression of Cx43 significantly increases the volume
fraction of regenerated bone relative to the amount of
bone regenerated from transplantation of control
BMSCs (160, 161). These in vitro and in vivo results
suggest that increasing GJIC can be used as a strategy
to enhance periodontal bone tissue engineering. The
ubiquitous nature of GJIC makes such an approach
also applicable to other oral tissues.
A.4. Clinical prospects Success of a tissue engineering
strategy in a small animal model does not necessarily
translate into humans or even larger animals. Filling of
defects in a rodent is more readily achieved because of
the well-controlled geometry, smaller size and higher
remodeling rate. As the size of a defect gets larger, the
ability to engineer a vascular supply becomes more
difficult as cells must be within 100 lm of an oxygen
source to survive (162). To date, direct growth factor
delivery and blank or growth factor containing scaffolds
(i.e. conductive and inductive materials, respectively)
are the only strategies discussed above for periodontal
regeneration that have been used for human clinical
trials (16, 118). This is yet to be expanded to include a
specific autologous cell population.
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Delivery of growth factors such as recombinant
BMP-2 and BMP-7, approved by the United States Food
and Drug Administration for clinical use in 2004 (163),
PDGF, IGF-1 and fibroblast growth factor (FGF) signi-
ficantly enhance the repair of periodontal alveolar bone
defects when delivered locally. Specifically, rhBMP-2
increases alveolar defect bone height repair by 2Æ4-fold
and total bone area by 7Æ8-fold in a canine model, results
equivalent to or better than autografting (164–166). In
humans, application of rhBMP-2 lyophilized to xeno-
genic bone substitute Bio-Oss (Luitpold Pharmaceu-
ticals Inc., Shirley, NY, USA) to alveolar ridge defects
demonstrated a statistically significant enhancement of
vertical defect reduction when compared with Bio-Oss
alone (167). The first human clinical trial for periodontal
disease used rhPDGF ⁄ rhIGF-1 in a methylcellulose
vehicle and revealed 43Æ5% osseous defect fill in the
treated group compared to only 18Æ5% osseous defect fill
in the vehicle or surgery alone group (16). Additional
clinical trials are currently planned or in progress for
PDGF treatment of post-extraction sockets (U Ala-
bama*) and healing of periodontal defects (Virchow
Group), rhBMP-2 treatment of vertical and horizontal
alveolar defects associated with implants† and FGF
treatment for periodontal tissue regeneration‡ (168).
Given these preliminary clinical successes using a basic
scaffold and single or dual growth factors for periodontal
defect regeneration, it is logically anticipated that
significant improvement can be expected in the near
future through application of optimized scaffold, cell,
and signalling combinations as discussed in the previous
sections. Furthermore, the combinations discovered for
periodontal bone tissue engineering will serve as a
fundamental starting point for in vivo engineering of
other mineralized tissues such as dentin and cementum.
B. Temporomandibular joint
The articulating joint is a complex system that is
regularly subjected to trauma, metabolic and inflam-
matory processes. Over 30 million Americans and
countless more worldwide suffer from some debilitation
of the joints and thus development of interventive and
regenerative cures is a global priority. Conventional
joint treatment methods such as Pridie’s perforations,
microfractures or subchondral abrasion lead to less than
adequate results in about 50% of cases in joints such as
the knee. These techniques often lead to the formation
of fibrocartilaginous scar tissue whose biomechanical
properties are significantly inferior to those of hyaline
cartilage. Most of the cell, scaffold and signalling
strategies discussed in section IV.A.1–A.3 can be applied
to engineering of functional cartilage and underlying
bone. TMJ engineering requires optimization of these
combinations for shape specification and bone ⁄ cartilage
interface formation.
B.1. Cells and scaffolds To overcome the drawbacks
inherent in traditional surgical methods of TMJ treat-
ment, alternative methods have been developed such as
osteochondral or chondrocyte allografts and autografts
[e.g. Carticel (Genzyme Corporation, Cambridge, MA,
USA), ChondroSelect (TiGenix, Leuven, Belgium)]
and progress in regenerative medical approaches for
both bone and cartilage is promising. Chondrocytes
seeded on materials like PGA (169–171) and collagen
(172, 173) develop cartilage-like structures that express
markers of chondrocyte differentiation and have com-
positions similar to normal articular cartilage. A num-
ber of joint repair studies suggest that these strategies
have merit (32, 33, 174–176). For a review of scaffold
technologies applicable to TMJ regeneration, please see
sections III and IV.A.2 of this article.
B.2. Signals In many ways, cartilage repair is more
complicated than bone regeneration. Mesenchymal
stem cells can be differentiated into chondrocytes in
cartilage defects, but the regenerated tissue rarely
matches the normal structure and function of mature
endogenous cartilage (177). Sustained delivery of appro-
priate growth factors such as basic FGF (bFGF), trans-
forming growth factor (TGF)-b and Sox9 is necessary for
cartilage regeneration. Basic FGF is one of the most
potent substances for chondrocyte proliferation and
differentiation because it can trigger a cascade of events
in the cartilage repair process (178). Both in vivo
injection and ex vivo delivery of virus encoding bFGF by
chondrocytes into rabbit knee joints can enhance artic-
ular cartilage repair (179, 180). The TGF-b superfamily,
including the BMPs and TGF-b1, has been shown to
promote chondrogenesis by regulating differentiation of
certain precursor cells (181). TGF-b1 can stimulate
proteoglycan and collagen synthesis (182) and MSCs
transduced by virus expressing TGF-b1 can enhance
*Biohorizons Implant Systems (Birmingham, AL, USA).
†Nobel Biocare (Goteborg, Sweden).
‡Kaken Pharmaceutical (New York, NY, USA).
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cartilage repair of osteochondral defects in athymic rats
(183). Sox9 is also a potential regulator of cartilage
regeneration because it is one of the earliest transcription
factors required for differentiation of MSCs towards a
chondrogenic lineage (184). Viral-mediated Sox9 over-
expression in chondrocytes derived from human os-
teoarthritic articular cartilage allows restoration of major
ECM components proteoglycan and type II collagen to
levels similar to those of healthy articular cartilage (185).
These gene therapy strategies can be widely applied to
joint repair and will enhance regeneration of a func-
tional TMJ in concert with appropriate delivery vehicles.
B.3. Clinical prospects To date, there is no ideal solution
to engineer a functional TMJ replacement. Allografts
are associated with donor site morbidity and are poorly
shaped for placement into defects and alloplastics do
not respond to normal biochemical or mechanical
signals (31, 186). Engineering a functional osteochon-
dral graft will require the production of both bone and
cartilage with a defined interface. Strides have been
made in engineering of these tissues separately (187–
189) and initial experiments have demonstrated simul-
taneous formation of bone and cartilage with a miner-
alized interface in vivo in mice (30, 190). In this
investigation, image-based design followed by solid
free-form fabrication to control scaffold size and shape
was used to generate a biphasic poly-L-lactic acid
(PLLA) ⁄ HA composite scaffold (30, 190) (Fig. 2a and
b). Differentiated pig chondrocytes and Ad.BMP7
transduced human gingival fibroblasts were seeded
onto the polymer and HA, respectively, and implanted
subcutaneously into N:Nih-bg-nu-xid immunocompro-
mised mice (30, 190). After 4 weeks, marrow-contain-
ing vascularized bone, mature cartilage and a defined
mineralized interface were formed (30, 190) (Fig. 2c).
This pioneering study provides proof of principle evi-
dence for the fabrication of a physiological osteochon-
dral graft that may be further developed for clinical use.
C. Skin and oral mucosa
Engineering of both skin and mucosal equivalents is
essential for the aesthetic reconstruction of individuals
disfigured by trauma, resective surgery or severe burns.
Skin is composed of layered dermis and epidermis in a
configuration that must be preserved for optimum
regeneration. The first description of skin grafting
occurred over 2500 years ago by the Hindu Tilemaker
Caste, in which skin grafting was used to reconstruct
noses that were amputated as a means of judicial
punishment (191). However, the first attempts to repair
damaged skin and mucosa with an engineered graft did
not occur until the 1980s. Investigators derived cul-
tured epithelial sheets from a small biopsy and reintro-
duced them to the patient for treatment of burns (192)
and for intra-oral grafting (193). Indeed, skin with both
dermal and epidermal components was the first FDA
approved tissue engineered construct that has been put
into clinical practice.
C.1. Cells All of the skin regeneration products
approved by the FDA rely on cells derived from
neonatal foreskin (194). Derivation of fibroblasts from
a single source such as foreskin controls for factors such
as cell age, gender and anatomic location. The cells of
one foreskin have proliferative potential capable of
providing starting cells for over 80 000 m of final
tissue-engineered product (194). Tissue engineered






Fig. 2. Tissue Engineering in Practice – Temporomandibular Joint
(30). (a) Image-based design of a theoretical site-specific implant
for temporomandibular joint engineering using solid free-form
fabrication. (b) A composite scaffold consisting of PLLA was seeded
with differentiated porcine chondrocytes and hydroxyapatite
(HA) seeded with Ad.BMP7 transduced gingival fibroblasts was
implanted subcutaneously into immunocompromised mice. (c)
Four weeks post-transplant harvested implants were sectioned
and analysed for presence of osteo-chondral structures. Cartilage
(arrows) and bone (*) were observed separated by a defined
interface (dotted line) [Adapted with permission from (30)].
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expandability and immune tolerance capabilities of a
cell population. Derivation of new or modification of
existing populations of cells with these characteristics is
essential for successful engineering of all tissues.
Though the oral mucosa comprises <5% of the total
surface of the human body it is a highly specialized
tissue. The oral mucosa, like the skin, is made up of
stratified squamous epithelium overlying a supportive
lamina propria. However, unlike the skin, mucosa may
be non-keratinized or keratinized, does not contain hair
follicles and may be further specialized to convey
sensations such as taste. Ideal engineering of oral mucosa
would allow reproduction of a physiologically correct
‘full-thickness’ tissue. This mucosa should have three
distinct layers: the lamina propria, basement membrane,
and stratified squamous epithelium. In vivo the lamina
propria consists of an abundant ECM network of
collagen and elastin fibers that support a dense fibroblast
population. The lamina propria is also responsible for
support of vascular components, lymphatic vessels,
nerves and salivary gland ducts. Early efforts to engineer
monolayer or multilayer epithelial sheets neglected to
generate this supportive lamina propria (195). Above the
lamina propria, stratified squamous epithelium rests on a
continuous basement membrane. The epithelial layer is
made up of densely packed keratinocytes that differen-
tiate as they migrate to the surface. This results in the
generation of four distinct layers of cells: the basal layer,
spinous layer, granular layer and keratinized layer.
Although difficult, it is possible to mimic this layered
differentiation in vitro by culturing the keratinocytes at
an air-liquid interface in defined medium containing
keratinocyte growth factors (196, 197). Multilayer cul-
ture of gingival keratinocytes has met with some clinical
success and is useful for in vitro biocompatibility testing
and oral biology research. Commercially available prod-
ucts include SkinEthic’s gingival epithelium and kerati-
nized stratified squamous epithelial products EpiOral§
and EpiGigival.§
C.2. Scaffolds and signals To move beyond current
gingival epithelium products, a full-thickness engi-
neered mucosa with intact lamina propria is needed.
This requires engineered scaffolds capable of supporting
fibroblast infiltration with minimum resulting shrink-
age and controlled biodegradation (198). Scaffolds used
for mucosa and skin reconstruction include natural
derivatives such as acellular dermis, ECM protein-based
scaffolds, synthetic materials and hybrid scaffolds of
both natural and synthetic matrices. Extensive reviews
of these materials and their use for skin and mucosa
engineering have been published elsewhere (198).
C.3. Clinical prospects Mucosal and gingival grafts are
desired to augment intraoral reconstructive surgery,
periodontal surgical procedures and to repair defects left
by gingival recession. In the past decade, research for
development of an engineered oral mucosa focused on
introducing new dermal scaffolds and improving epi-
thelial cell culture methods (198). The ability to
produce a supportive dermis with a functional epithe-
lial layer is limited by current dermal matrices and poor
differentiation of multilayered keratinocyte constructs.
To address these issues, investigators are working to
optimize the cell source, culture conditions and choice
of scaffold. Since 1996, many combinations of cell type,
culture condition and scaffold have been tested both
in vitro and in vivo. For example, cells derived from oral
tissues have been used successfully for ocular recon-
struction in rabbits (rabbit oral mucosa cells ⁄ human
amniotic membrane scaffold) (199), intra-oral grafting
in humans (human oral fibroblast cells ⁄ AlloDerm
scaffold) (25) and burn treatment in humans [human
oral fibroblast cells ⁄ AlloDerm scaffold (LifeCell Cor-
poration, Branchburg, NJ, USA)] (26). Future direc-
tions include expansion of these applications with a
commercially available engineered oral mucosa product
similar to skin substitutes Dermagraft (200; Advanced
Biohealing Inc., Westport, CT, USA) and Apligraf
(Organogenesis Inc., Canton, MA, USA) used for
coverage of burns and acute wounds (201). It should,
however, be noted that even without a commercial
full-thickness mucosa, clinical success using the skin
substitute Dermagraft has been reported (200) for pre-
prosthetic intraoral vestibular extension (202) (Fig. 3).
D. Salivary gland
Loss of salivary gland function can result as a pharma-
cological side-effect, from radiation therapy or as a
consequence of autoimmune diseases such as Sjogren’s
syndrome. Saliva is a complex hypotonic solution that
carries water, electrolytes, bioactive proteins and pep-
tides into the oral cavity (203). Loss of salivary flow,
referred to as xerostomia, significantly impacts quality
of life and predisposes affected individuals to caries,§MatTek Corp., Ashland, MA, USA.
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dysphagia, dysgeusia and mucosal infection. Although
most pharmacological loss-of-function is reversible,
there remain 2–4 million people in the US with
irreversible destruction of salivary gland tissue (5).
Tissue engineering of a salivary gland substitute or
replacement is one way to treat these patients (5). To
accomplish this complex task, three objectives must be
satisfied: identification of a cell population capable of
appropriate differentiation and fluid movement, opti-
mization of scaffold material properties and definition
of ideal culture conditions and ECM components. This
section will focus on current salivary gland tissue
engineering strategies, which combine cell transplan-
tation and gene transfer with engineered scaffolds to
generate an artificial salivary gland substitute. Signals
that could potentially be used to enhance salivary gland
function are also discussed.
D.1. Cells There are many varieties of human salivary
glands. Besides the paired major salivary glands, the oral
cavity contains up to one thousand additional minor
salivary glands embedded in the lamina propria of the
oral mucosa. Each of the three types of paired major
glands (parotid, submandibular and sublingual) secretes
a unique fluid composed of mixed mucous and serous
secretions depending on the cellular content of the
gland. The major salivary gland most important to tissue
engineers is the parotid due its location and size, serous
or ‘watery’ saliva secretion profile and tendency to be
damaged by radiation or autoimmune disease. The
parotid is the largest of the salivary glands and is located
in the subcutaneous tissue of the face, over the man-
dibular ramus and anterior to the ear. The parotid is the
main producer of serous saliva in the oral cavity and loss
of its function is severely detrimental to the patient. All
major salivary glands consist of a mesenchymal scaffold,
which is host to four distinct epithelial cell types: acinar,
duct, myoepithelial and basal cells. Saliva is secreted by
the mucous and serous acinar cells, modified by the duct
cells and transported to the oral cavity with the support
of myoepithelial and basal cells. Recapitulation of
physiological salivary gland structure and function is a
challenging issue that researchers, including tissue
engineers, are just beginning to understand.
Natural salivary glands are made up of highly
specialized cells capable of fluid secretion, modification
and directional movement. The challenge of culturing
and implanting cells capable of all of these functions is
the primary focus of salivary gland tissue engineers.
Efforts with a human ductal epithelial salivary gland
cell line (HSG) were promising when the cells were
found to respond to ECM in culture (204), form
monolayers on PLLA scaffolds (205) and have the
systems necessary to generate osmotic gradients for
saliva formation (206). Unfortunately, it was later
found that HSG cells lack the ability to form tight
junctions and thus are not capable of supporting
unidirectional fluid movement (207). To circumvent
these issues, primary salivary gland epithelial cells have
been isolated from mouse (208) and non-human
primates (209). Primary parotid cultures from rhesus
monkey are duct-like, can form polarized monolayers
and are able to mediate fluid movement after applica-
tion of an external osmotic gradient (209).
(a) (b)
(c) (d)
Fig. 3. Tissue Engineering in Prac-
tice – Oral Mucosa (202). Tissue
engineered dermal replacement
DermaGraft was used in place of
autologous tissue for vestibuloplasty
post-squamous cell carcinoma
removal. (a) Post-surgical scars
limited patient closure. (b) Intraoral
view shows insufficient vestibular
depth with extensive fibrous and
muscular insertion. (c) Mucogingival
junction and periosteal dissection
was followed by implantation of
Dermagraft. (d) Patient demon-
strating improved vestibular depth
after 3 months. [Reprinted with
permission from (202)].
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An additional cellular strategy includes identification
and use of an autologous stem cell population. Salivary
gland epithelial progenitor cells may be identified by
their expression of alpha6-beta1 integrin receptors
(210) and have been recently noted as a novel
autologous cell population for use in salivary gland
tissue engineering (211). Rat BMSCs may also have the
ability to trans-differentiate into alpha-amylase
expressing acinar cells (212). This implies that stem
cells external to the salivary gland may be of utility.
With the number of cellular options increasing, a
deeper understanding of molecular control and coor-
dination of fluid and protein secretion is necessary.
Application can then be facilitated by appropriately
designed scaffolds.
D.2. Scaffolds Device design for an ideal artificial sali-
vary gland consists of a blind end tube made from a
porous, biodegradable material (5). This scaffold is
envisioned to be coated with matrix components on
the inner surface of the tube to promote formation of
polarized epithelial cell ‘ducts’ capable of unidirectional
fluid movement. Such a device could then be implanted
into the buccal mucosa with an exit into the oral cavity,
similar to a natural parotid gland duct. This device
would then allow secretion of fluids and salts from the
body into the oral cavity, mimicking a natural salivary
gland. Scaffold selection for salivary gland replacement
is taking cues from materials used to engineer replace-
ments for other tubular structures such as intestine,
vasculature, ureter and the trachea (5). To this end,
tissue compatibility and in vitro analysis of scaffolds of
PLLA (205), poly-glycolic acid coated with PLLA (205),
PEG-terephthalate ⁄ poly(butylene terephthalate) (PEG-
TPBT) (213), chitosan (214) and collagen ⁄ matrigel
(215) have been tested. Results show acceptable levels
of local inflammation around PLLA and PGA-PLLA
when implanted adjacent to the buccal mucosa in mice
(216) as well as in vitro formation of polarized mono-
layers on PEG-TPBT scaffolds with successful mainte-
nance of acinar cells (213).
D.3. Signals Unlike acinar cells, traditional ductal epi-
thelial cells are incapable of fluid secretion. As isolation
and expansion of acinar cells in vitro is currently not
possible, identification and localization of membrane
proteins required for ionic gradient formation and fluid
flow in acinar cells will inform efforts to modify ductal
cell populations using gene transfer. Acinar cells
require four membrane proteins to generate an osmotic
gradient for unidirectional fluid movement: (i) the
N+K+-ATPase used to maintain membrane potential,
(ii) a Ca2+activated K+ channel, (iii) the secretory
isoform of the Na+ ⁄ K+ ⁄ 2Cl) cotransporter and (iv) the
apical membrane bound Ca2+activated Cl) channel (5,
217). Salivation occurs in response to agonists that
generate an increase in intracellular Ca2+ concentration
and is facilitated by osmotic gradient directed fluid
movement through water channels in the apical
membrane known as aquaporins (AQP) (217). It is
now recognized that isolated ductal epithelial cells lack
expression of AQP and as such cannot mediate fluid
movement (209). Re-introduction of transient AQP
expression using adenoviral transduction has been
successful in rhesus monkey parotid duct cells in vitro
(218), rat and mini-pig salivary gland tissue in vivo
(219) and is the subject of an ongoing clinical trial
(168).
In addition to re-engineering of ductal epithelial cells,
modification of potential salivary gland scaffolds to
optimize monolayer culture is necessary. Purified
matrix proteins already examined for their ability to
support in vitro HSG cell culture include fibronectin,
laminin, collagen I, collagen IV and gelatin (205). In the
absence of pre-adsorbed proteins, HSG cells did not
attach to PLLA or PGA-PLLA (205). However, on
matrix protein-coated biomaterials, HSG cells were able
to form a uniform monolayer, which was dependent on
time and protein concentration (205).
D.4. Clinical prospects Current treatment of salivary
gland hypofunction includes pharmacological stimu-
lation of remaining acinar tissue and palliative care
with mucosal lubricating agents (220). To date,
regenerative efforts have been focused on both repair
and replacement. Indeed, attempts to restore salivary
flow by in vivo transduction of adenovirus encoding
AQP1 into remaining glandular tissue of patients
treated with radiation for head and neck cancer is the
first human craniofacial repair gene therapy clinical
trial and is currently ongoing (168, 219). Replace-
ment strategies include salivary gland transplantation
and re-engineering of new glandular tissue as dis-
cussed above (221, 222). Although there have not yet
been any reports of salivary gland prototype experi-
ments in vivo, the work carried out to date supports
the idea that an engineered gland may be a future
reality.
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V. Unique challenges and opportunities in
oral and craniofacial tissue engineering
The biomimetic approaches discussed above, along with
all other strategies to reproduce the design rules of
biological systems, do not completely mimic nature.
However, if the selected biomimicry is rationally
designed into a biomaterial, then the biological system
will be able to respond in a more controlled, predictable
and efficient manner, providing an exciting new arena
for biomaterials research and development. Regenera-
tion of oral and craniofacial tissues requires synthesis of
engineering, clinical and basic science. The tissues of
this region are complex and engineering these tissues
presents many unique design challenges. In the cra-
niofacial region, maintaining or restoring aesthetics in
addition to restoring structure and function result in a
more complex design problem than in other regions of
the body. In oral tissue engineering, it is also necessary
to consider the microbial environment and the poten-
tially altered host immune response (39).
Many oral structures are hybrid tissues. For exam-
ple, engineering the periodontium requires growth of
alveolar bone, cementum and the PDL. Engineering a
tooth requires the development of dentin and enamel
in the exquisite organic ⁄ inorganic organization that
provides mechanical function to these tissues. Engi-
neering of a TMJ requires the creation of functional
bone and cartilage. For each of these hybrid tissue
systems, it is also necessary to recreate the functionally
graded structures that result from normal develop-
ment. Simply creating dentin and enamel without a
graded dentin-enamel junction, or bone and cartilage
without the appropriate transition zone between the
two tissues may not be sufficient to impart function-
ality. While there are significant challenges in engi-
neering hybrid oral and craniofacial tissues, there are
also significant opportunities for these tissues to serve
as model systems for engineering other tissues and
organs of the body.
Developmental differences between the craniofacial
and appendicular skeletons must be considered when
orchestrating craniofacial tissue engineering strategies
(39). The appendicular skeleton is derived from the
mesoderm and bone forms via endochondral ossifica-
tion. On the other hand, the cranial skeleton is derived
from the cranial neural crest and paraxial mesoderm
and its bones are formed via both intramembranous
and endochondral ossification (39, 223). Given the
different developmental processes and the goal of
recapitulating development in tissue engineering, it is
reasonable to suggest that engineering of craniofacial
bones might necessitate approaches different from
those used to engineer long bones. This notion is
supported by differences in osteoblast response to
mechanical and molecular signals, depending on the
origin of the osteoblast (39, 224–226).
The accessibility of the oral environment and ability
to create minimally invasive models of hybrid tissues
renders oral tissues convenient platforms for testing
tissue engineered prototypes (39, 227, 228). In this
regard, oral and craniofacial tissue engineering can
have a two-fold impact that extends beyond dentistry.
First, advances initially made in dentistry because of
the relatively simple surgical models can be translated
into other organ systems. Second, technologies devel-
oped outside of dentistry can be tested in oral models.
For example, one of the most frequently used
screening tools for bone tissue engineering is the
critical size calvarial defect model (229). As a second
example, the hybrid tissue systems of the perio-
dontium, TMJ, cranial suture and mineralized tissues
of the tooth can provide insight into how to design a
composite tissue consisting of multiple cell types
(190). As a third example, oral and craniofacial-
derived stem cells from the dental pulp, PDL and
cranial sutures have utility in non-dental and non-
craniofacial applications (77). The impact of the
bidirectional synergy between engineering oral tissues
and engineering tissues elsewhere in the body is that
oral and craniofacial tissue engineering is an integral
component of the larger field of tissue engineering
and should not be viewed as dental researchers
solving dental problems in isolation.
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